Anika Therapeutics Stock Current Valuation
| ANIK Stock | USD 17.28 0.35 2.07% |
Valuation analysis of Anika Therapeutics helps investors to measure Anika Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Fairly Valued
Today
Please note that Anika Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Anika Therapeutics is based on 3 months time horizon. Increasing Anika Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Anika Therapeutics' intrinsic value may or may not be the same as its current market price of 17.28, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 17.28 | Real 16.66 | Hype 17.28 | Naive 17.55 |
The intrinsic value of Anika Therapeutics' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Anika Therapeutics' stock price.
Estimating the potential upside or downside of Anika Therapeutics helps investors to forecast how Anika stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Anika Therapeutics more accurately as focusing exclusively on Anika Therapeutics' fundamentals will not take into account other important factors: Anika Therapeutics Company Current Valuation Analysis
Anika Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Anika Therapeutics Current Valuation | 213.12 M |
Most of Anika Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Anika Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Anika Therapeutics has a Current Valuation of 213.12 M. This is 98.52% lower than that of the Biotechnology sector and 98.28% lower than that of the Health Care industry. The current valuation for all United States stocks is 98.72% higher than that of the company.
Anika Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Anika Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Anika Therapeutics could also be used in its relative valuation, which is a method of valuing Anika Therapeutics by comparing valuation metrics of similar companies.Anika Therapeutics is currently under evaluation in current valuation category among its peers.
Anika Fundamentals
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.0401 | ||||
| Profit Margin | (0.59) % | ||||
| Operating Margin | (0.64) % | ||||
| Current Valuation | 213.12 M | ||||
| Shares Outstanding | 14.65 M | ||||
| Shares Owned By Insiders | 3.40 % | ||||
| Shares Owned By Institutions | 89.79 % | ||||
| Number Of Shares Shorted | 402.31 K | ||||
| Price To Earning | 42.30 X | ||||
| Price To Book | 1.38 X | ||||
| Price To Sales | 1.54 X | ||||
| Revenue | 166.66 M | ||||
| Gross Profit | 80.23 M | ||||
| EBITDA | (11.23 M) | ||||
| Net Income | (82.67 M) | ||||
| Cash And Equivalents | 87.78 M | ||||
| Cash Per Share | 6.01 X | ||||
| Total Debt | 29.04 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 6.37 X | ||||
| Book Value Per Share | 12.24 X | ||||
| Cash Flow From Operations | (1.79 M) | ||||
| Short Ratio | 5.20 X | ||||
| Earnings Per Share | (6.64) X | ||||
| Price To Earnings To Growth | 3.60 X | ||||
| Target Price | 26.5 | ||||
| Number Of Employees | 357 | ||||
| Beta | 0.86 | ||||
| Market Capitalization | 253.08 M | ||||
| Total Asset | 270.63 M | ||||
| Retained Earnings | 128.05 M | ||||
| Working Capital | 132.25 M | ||||
| Current Asset | 176.43 M | ||||
| Current Liabilities | 17.28 M | ||||
| Net Asset | 270.63 M |
About Anika Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Anika Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Anika Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Anika Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Anika Therapeutics Piotroski F Score and Anika Therapeutics Altman Z Score analysis. For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Medical Equipment space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anika Therapeutics. If investors know Anika will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anika Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Anika Therapeutics is measured differently than its book value, which is the value of Anika that is recorded on the company's balance sheet. Investors also form their own opinion of Anika Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Anika Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anika Therapeutics' market value can be influenced by many factors that don't directly affect Anika Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anika Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anika Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anika Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.